Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: Systematic review and meta-analysis of randomised clinical trials

BMJ (Online)

Volumn 347, Issue 7923, 2013, Pages

  Litton, Edward ^a,b   Xiao, Jing ^a   Ho, Kwok M ^a,c  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; FERRITIN; HEMOGLOBIN; IRON; TRANSFERRIN;

ALLOGENIC BLOOD TRANSFUSION; ANAPHYLAXIS; ANEMIA; BLOOD TRANSFUSION; CLINICAL EVALUATION; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; HUMAN; INFECTION; INFECTION RISK; IRON THERAPY; META ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

BACTERIAL INFECTIONS; BLOOD TRANSFUSION; HUMANS; INFUSIONS, INTRAVENOUS; IRON; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84883779160     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f4822     Document Type: Review

References (99)

1. Mclean E. Worldwide prevalence of anaemia 1993-2005. World Health Organization, 2008.
2. Isbister JP, Shander A, Spahn DR, Erhard J, Farmer SL, Hofmann A. Adverse blood transfusion outcomes: establishing causation. Transfus Med Rev 2011;25:89-101.
3. Goodnough LT. Iron deficiency syndromes and iron-restricted erythropoeisis. Transfusion 2012;52:1584-92.
4. KDOQI, National Kidney Foundation. II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 2006;47(5 suppl 3):S16-85.
5. Hofmann A, Farmer S, Towler SC. Strategies to preempt and reduce the use of blood products: an Australian perspective. Curr Opin Anaesthesiol 2012;25:66-73.
6. Shander A, Spence RK, Auerbach M. Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents? Transfusion 2010;50:719-32.
7. Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs 2009;69:739-56.
8. Fishbane S. Review of issues relating to iron and infection. Am J Kidney Dis 1999;34(4 suppl 2):S47-52. (Pubitemid 29473042)
9. Maynor L, Brophy DF. Risk of infection with intravenous iron therapy. Ann Pharmacother 2007;41:1476-80. (Pubitemid 47311367)
10. Notebaert E, Chauny JM, Albert M, Fortier S, Leblanc N, Williamson DR. Short-term benefits and risks of intravenous iron: a systematic review and meta-analysis. Transfusion 2007;47:1905-18. (Pubitemid 47440059)
11. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9, W64.
12. Friedrich JO, Adhikari NK, Beyene J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol 2007;7:5.
13. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
14. Neeru S, Nair NS, Rai L. Iron sucrose versus oral iron therapy in pregnancy anemia. Indian J Community Med 2012;37:214-8.
15. Adhikary L, Acharya S. Efficacy of IV iron compared to oral iron for increment of haemoglobin level in anemic chronic kidney disease patients on erythropoietin therapy. JNMA J Nepal Med Assoc 2011;51:133-6.
16. Agarwal R, Rizkala AR, Bastani B, Kaskas MO, Leehey DJ, Besarab A. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 2006;26:445-54. (Pubitemid 44971735)
17. Aggarwal HK, Nand N, Singh S, Singh M, Hemant, Kaushik G. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physicians India 2003;51:170-4. (Pubitemid 44227894)
18. Al RA, Unlubilgin E, Kandemir O, Yalvac S, Cakir L, Haberal A. Intravenous versus oral iron for treatment of anemia in pregnancy: a randomized trial. Obstet Gynecol 2005;106:1335-40. (Pubitemid 41668954)
19. Al-Momen AK, al-Meshari A, al-Nuaim L, Saddique A, Abotalib Z, Khashogji T, et al. Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy. Eur J Obstet Gynecol Reprod Biol 1996;69:121-4. (Pubitemid 26338317)
20. Allen RP, Adler CH, Du W, Butcher A, Bregman DB, Earley CJ. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep Med 2011;12:906-13.
21. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-48.
22. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-7. (Pubitemid 41079845)
23. Auerbach M, Silberstein PT, Webb RT, Averyanova S, Ciuleanu TE, Shao J, et al. Darbepoetin alfa 300 or 500 mug once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol 2010;85:655-63.
24. Bastit L, Vandebroek A, Altintas S, Gaede B, Pinter T, Suto TS, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008;26:1611-8.
25. Bayoumeu F, Subiran-Buisset C, Baka NE, Legagneur H, Monnier-Barbarino P, Laxenaire MC. Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route. Am J Obstet Gynecol 2002;186:518-22. (Pubitemid 34234167)
26. Beck-da-Silva L, Piardi D, Soder S, Rohde LE, Pereira-Barretto AC, de Albuquerque D, et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol 2013 doi:10.1016/j.ijcard.2013.04.181
27. Bencaiova G, von Mandach U, Zimmermann R. Iron prophylaxis in pregnancy: intravenous route versus oral route. Eur J Obstet Gynecol Reprod Biol 2009;144:135-9.
28. Bhandal N, Russell R. Intravenous versus oral iron therapy for postpartum anaemia. BJOG 2006;113:1248-52. (Pubitemid 44581513)
29. Birgegard G, Schneider K, Ulfberg J. High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron. Vox Sang 2010;99:354-61.
30. Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet 2008;101:67-73.
31. Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 2005;100:c55-62. (Pubitemid 40868986)
32. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007;18:975-84. (Pubitemid 46434515)
33. Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 2010;116:522-5.
34. Edwards TJ, Noble EJ, Durran A, Mellor N, Hosie KB. Randomized clinical trial of preoperative intravenous iron sucrose to reduce blood transfusion in anaemic patients after colorectal cancer surgery. Br J Surg 2009;96:1122-8.
35. Evstatiev R, Alexeeva O, Bokemeyer B, Chopey I, Felder M, Gudehus M, et al. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:269-77.
36. Friel JK, Andrews WL, Hall MS, Rodway MS, Keith M, McCloy UC, et al. Intravenous iron administration to very-low-birth-weight newborns receiving total and partial parenteral nutrition. JPEN J Parenter Enteral Nutr 1995;19:114-8.
37. Froessler B, Cocchiaro C, Saadat-Gilani K, Hodyl N, Dekker G. Intravenous iron sucrose versus oral iron ferrous sulfate for antenatal and postpartum iron deficiency anemia: a randomized trial. J Matern Fetal Neona 2013;26:654-9.
38. Garrido-Martin P, Nassar-Mansur MI, de la Llana-Ducros R, Virgos-Aller TM, Rodriguez Fortunez PM, Avalos-Pinto R, et al. The effect of intravenous and oral iron administration on perioperative anaemia and transfusion requirements in patients undergoing elective cardiac surgery: a randomized clinical trial. Interac Cardiovasc Thorac Surg 2012;15:1013-8.
39. Grote L, Leissner L, Hedner J, Ulfberg J. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Mov Disord 2009;24:1445-52.
40. Hedenus M, Birgegard G, Nasman P, Ahlberg L, Karlsson T, Lauri B, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007;21:627-32. (Pubitemid 46444544)
41. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231-42.
42. Hulin S, Durandy Y. [Post-haemodilution anaemia in paediatric cardiac surgery: benefit of intravenous iron therapy]. Ann Fr Anesth Reanim 2005;24:1262-5. (Pubitemid 41463411)
43. Karkouti K, McCluskey SA, Ghannam M, Salpeter MJ, Quirt I, Yau TM. Intravenous iron and recombinant erythropoietin for the treatment of postoperative anemia. Can J Anaesth 2006;53:11-9. (Pubitemid 43230987)
44. Kasper SM, Lazansky H, Stark C, Klimek M, Laubinger R, Borner U. Efficacy of oral iron supplementation is not enhanced by additional intravenous iron during autologous blood donation. Transfusion 1998;38:764-70. (Pubitemid 28381746)
45. Khalafallah A, Dennis A, Bates J, Bates G, Robertson IK, Smith L, et al. A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy. J Intern Med 2010;268:286-95.
46. Kim YH, Chung HH, Kang SB, Kim SC, Kim YT. Safety and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia: a phase IV, open-label, prospective, randomized study. Acta Haematol 2009;121:37-41.
47. Kim YT, Kim SW, Yoon BS, Cho HJ, Nahm EJ, Kim SH, et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 2007;105:199-204. (Pubitemid 46441460)
48. Kochhar PK, Kaundal A, Ghosh P. Intravenous iron sucrose versus oral iron in treatment of iron deficiency anemia in pregnancy: a randomized clinical trial. J Obstet Gynaecol Res 2013;39:504-10.
49. Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 2011;118:3222-7.
50. Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008;103:1182-92. (Pubitemid 351677967)
51. Li H, Wang SX. Intravenous iron sucrose in peritoneal dialysis patients with renal anemia. Perit Dial Int 2008;28:149-54. (Pubitemid 351552398)
52. Li H, Wang SX. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. Blood Purif 2008;26:151-6. (Pubitemid 351416698)
53. Li H. [Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study.] Zhonghua Yi Xue Za Zhi 2009;89:457-62.
54. Lindgren S, Wikman O, Befrits R, Blom H, Eriksson A, Granno C, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol 2009;44:838-45.
55. Maccio A, Madeddu C, Gramignano G, Mulas C, Sanna E, Mantovani G. Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study. Oncologist 2010;15:894-902.
56. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;50:1694-9. (Pubitemid 26364277)
57. Madi-Jebara SN, Sleilaty GS, Achouh PE, Yazigi AG, Haddad FA, Hayek GM, et al. Postoperative intravenous iron used alone or in combination with low-dose erythropoietin is not effective for correction of anemia after cardiac surgery. J Cardiothorac Vasc Anesth 2004;18:59-63. (Pubitemid 38240762)
58. McMahon LP, Kent AB, Kerr PG, Healy H, Irish AB, Cooper B, et al. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial. Nephrol Dial Transplant 2010;25:920-6.
59. Meyer MP, Haworth C, Meyer JH, Commerford A. A comparison of oral and intravenous iron supplementation in preterm infants receiving recombinant erythropoietin. J Pediatr 1996;129:258-63. (Pubitemid 27483798)
60. Na HS, Shin SY, Hwang JY, Jeon YT, Kim CS, Do SH. Effects of intravenous iron combined with low-dose recombinant human erythropoietin on transfusion requirements in iron-deficient patients undergoing bilateral total knee replacement arthroplasty. Transfusion 2011;51:118-24.
61. Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008;51:103-12.
62. Olijhoek G, Megens JG, Musto P, Nogarin L, Gassmann-Mayer C, Vercammen E, et al. Role of oral versus IV iron supplementation in the erythropoietic response to rHuEPO: a randomized, placebo-controlled trial. Transfusion 2001;41:957-63. (Pubitemid 32642770)
63. Onken JE, Bregman DB, Harrington RA, Morris D, Acs P, Akright B, et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion 2013 doi:10. 1111/trf.12289
64. Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008;26:1619-25.
65. Pollak A, Hayde M, Hayn M, Herkner K, Lombard KA, Lubec G, et al. Effect of intravenous iron supplementation on erythropoiesis in erythropoietin-treated premature infants. Pediatrics 2001;107:78-85. (Pubitemid 32055419)
66. Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009;4:386-93.
67. Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 2011;26:1599-607.
68. Schaller G, Scheiber-Mojdehkar B, Wolzt M, Puttinger H, Mittermayer F, Horl WH, et al. Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients. Kidney Int 2005;68:2814-22. (Pubitemid 43251028)
69. Schindler E, Scholz S, Boldt J, Zickmann B, Knothe C, Dietrich G, et al. [Effectiveness of oral versus parenteral iron substitution in autologous blood donors]. Infusionsther Transfusionsmed 1994;21:236-41. (Pubitemid 24284219)
70. Schroder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, Herfarth H, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease-a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 2005;100:2503-9.
71. Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol 2008;199:435.
72. Serrano-Trenas JA, Ugalde PF, Cabello LM, Chofles LC, Lazaro PS, Benitez PC. Role of perioperative intravenous iron therapy in elderly hip fracture patients: a single-center randomized controlled trial. Transfusion 2011;51:97-104.
73. Shafi D, Purandare SV, Sathe AV. Iron deficiency anemia in pregnancy: intravenous versus oral route. J Obstet Gynaecol India 2012;62:317-21.
74. Singh H, Reed J, Noble S, Cangiano JL, Van Wyck DB. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis- stimulating agents for anemia: a randomized, controlled trial. Clin J Am Soc Nephrol 2006;1:475-82.
75. Singh K, Fong YF, Kuperan P. A comparison between intravenous iron polymaltose complex (Ferrum Hausmann) and oral ferrous fumarate in the treatment of iron deficiency anaemia in pregnancy. Eur J Haematol 1998;60:119-24. (Pubitemid 28082933)
76. Sloand JA, Shelly MA, Feigin A, Bernstein P, Monk RD. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 2004;43:663-70. (Pubitemid 38401881)
77. Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008;19:1599-605.
78. Steensma DP, Sloan JA, Dakhil SR, Dalton R, Kahanic SP, Prager DJ, et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 2011;29:97-105.
79. Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 2001;16:967-74. (Pubitemid 32440369)
80. Toblli JE, Lombrana A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007;50:1657-65. (Pubitemid 47562670)
81. Van Iperen CE, Gaillard CA, Kraaijenhagen RJ, Braam BG, Marx JJ, van de Wiel A. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med 2000;28:2773-8.
82. Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol 2007;110:267-78. (Pubitemid 47356650)
83. Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009;49:2719-28.
84. Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 2005;68:2846-56. (Pubitemid 43251032)
85. Verma S. Intravenous iron therapy versus oral iron in postpartum patients in rural areas. J S Asian Fed Obstet Gynaecol 2011;3:67-70.
86. Warady BA, Kausz A, Lerner G, Brewer ED, Chadha V, Brugnara C, et al. Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol 2004;19:655-61. (Pubitemid 38771738)
87. Weisbach V, Skoda P, Rippel R, Lauer G, Glaser A, Zingsem J, et al. Oral or intravenous iron as an adjuvant to autologous blood donation in elective surgery: a randomized, controlled study. Transfusion 1999;39:465-72. (Pubitemid 29233269)
88. Westad S, Backe B, Salvesen KA, Nakling J, Okland I, Borthen I, et al. A 12-week randomised study comparing intravenous iron sucrose versus oral ferrous sulphate for treatment of postpartum anemia. Acta Obstet Gynecol Scand 2008;87:916-23.
89. Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Critical care medicine 2008;36:2667-74.
90. Fleming RE, Ponka P. Iron overload in human disease. N Engl J Med 2012;366:348-59.
91. Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010;116:4754-61.
92. Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007;357:965-76. (Pubitemid 47367076)
93. Heming N, Letteron P, Driss F, Millot S, El Benna J, Tourret J, et al. Efficacy and toxicity of intravenous iron in a mouse model of critical care anemia. Crit Care Med 2012;40:2141-8.
94. Torres S, Kuo YH, Morris K, Neibart R, Holtz JB, Davis JM. Intravenous iron following cardiac surgery does not increase the infection rate. Surg Infect (Larchmt) 2006;7:361-6. (Pubitemid 46489579)
95. Ang O, Gungor M, Aricioglu F, Inanc D, Sagduyu H, Uysal V, et al. The effect of parenteral iron administration on the development of Staphylococcus aureus-induced experimental pyelonephritis in rats. Int J Exp Pathol 1990;71:507-11. (Pubitemid 20314605)
96. Locatelli F, Del Vecchio L. New erythropoiesis-stimulating agents and new iron formulations. Contrib Nephrol 2011;171:255-60.
97. Moore RA, Gaskell H, Rose P, Allan J. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord 2011;11:4.
98. Gafter-Gvili A, Rozen-Zvi B, Vidal L, Leibovici L, Vansteenkiste J, Gafter U, et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia- systematic review and meta-analysis of randomised controlled trials. Acta Oncol 2013;52:18-29.
99. Stewart GB, Altman DG, Askie LM, Duley L, Simmonds MC, Stewart LA. Statistical analysis of individual participant data meta-analyses: a comparison of methods and recommendations for practice. PLoS One 2012;7:e46042.